共 50 条
Tough Adhesive Hydrogel for Intraoral Adhesion and Drug Delivery
被引:6
|作者:
Wu, D. T.
[1
,2
,3
]
Freedman, B. R.
[1
,2
]
Vining, K. H.
[1
,2
,4
]
Cuylear, D. L.
[1
,2
]
Guastaldi, F. P. S.
[5
]
Levin, Y.
[6
]
Mooney, D. J.
[1
,2
,7
]
机构:
[1] Harvard Univ, Harvard John A Paulson Sch Engn & Appl Sci, Lab Cell & Tissue Engn, Cambridge, MA USA
[2] Harvard Univ, Wyss Inst Biolog Inspired Engn, Cambridge, MA USA
[3] Harvard Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA USA
[4] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[5] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA USA
[6] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA USA
[7] Harvard Univ, Harvard John A Paulson Sch Engn & Appl Sci, 29 Oxford St,Room 319, Cambridge, MA 02138 USA
基金:
美国国家卫生研究院;
关键词:
biocompatible materials;
tissue adhesives;
surgical tapes;
oral medicine;
oral lichen planus;
oral ulcers;
ORAL LICHEN-PLANUS;
BIOADHESIVE;
CLOBETASOL;
MANAGEMENT;
D O I:
10.1177/00220345221148684
中图分类号:
R78 [口腔科学];
学科分类号:
1003 ;
摘要:
Oral lichen planus (OLP) and recurrent aphthous stomatitis (RAS) are common chronic inflammatory conditions, manifesting as painful oral lesions that negatively affect patients' quality of life. Current treatment approaches are mainly palliative and often ineffective due to inadequate contact time of the therapeutic agent with the lesions. Here, we developed the Dental Tough Adhesive (DenTAl), a bioinspired adhesive patch with robust mechanical properties, capable of strong adhesion against diverse wet and dynamically moving intraoral tissues, and extended drug delivery of clobetasol-17-propionate, a first-line drug for treating OLP and RAS. DenTAl was found to have superior physical and adhesive properties compared to existing oral technologies, with similar to 2 to 100x adhesion to porcine keratinized gingiva and similar to 3 to 15x stretchability. Clobetasol-17-propionate incorporated into the DenTAl was released in a tunable sustained manner for at least 3 wk and demonstrated immunomodulatory capabilities in vitro, evidenced by reductions in several cytokines, including TNF-alpha, IL-6, IL-10, MCP-5, MIP-2, and TIMP-1. Our findings suggest that DenTAl may be a promising device for intraoral delivery of small-molecule drugs applicable to the management of painful oral lesions associated with chronic inflammatory conditions.
引用
收藏
页码:497 / 504
页数:8
相关论文